ClinicalTrials.gov record NCT07845162

Serum EBI-3 Protein Levels in Behçet's Disease

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 28, 2026

Serum Epstein-Barr Virus-induced Gene 3 Protein Levels in Patients With Behçet's Disease

StatusNot yet recruitingThe study has been registered but has not started enrolling. Sites and contacts may not be listed yet.
Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.
Healthy volunteersAcceptedPeople who do not have the condition being studied who are allowed to take part. Some studies include both people with the condition and healthy volunteers; others may enrol only healthy volunteers.
Age18 years old and older
SexAll
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This cross-sectional observational study measures blood levels of the protein EBI-3 in adults with Behçet's disease and in age-matched healthy controls. It compares average EBI-3 levels between the two groups and looks at how levels relate to disease activity and organ involvement. Measurements are taken at a single time point.

What it is studying. The study tests whether serum EBI-3 protein concentrations differ between people with Behçet's disease and healthy controls, and whether EBI-3 levels are associated with disease activity and with vascular, ocular, or neurological involvement.

What the researchers hope to learn. Scientific goals are to describe serum EBI-3 levels in Behçet's disease versus controls and to explore associations with disease activity and specific organ involvement (vascular, ocular, neurological).

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

This cross-sectional study aims to evaluate serum Epstein-Barr virus-induced gene 3 (EBI-3) protein levels in patients with Behçet's disease compared with healthy controls.

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of Behçet's disease according to the International Criteria for Behçet's Disease (cases)
  • Healthy individuals without autoimmune or inflammatory diseases (controls)
  • Written informed consent

Exclusion criteria

  • Other autoimmune disorders (RA, SLE, psoriatic arthritis, ankylosing spondylitis)
  • Acute or chronic infection
  • Malignancy or history of malignancy
  • Chronic liver disease or advanced chronic kidney disease
  • Pregnancy or lactation
  • Vasculitis caused by diseases other than Behçet's disease

Study description and what participation involves

The study's detailed description, as published on ClinicalTrials.gov.

Detailed description from the registry

Behçet's disease is a chronic multisystem inflammatory disorder. Serum EBI-3 protein levels may reflect inflammatory activity. This observational study will include adult patients diagnosed with Behçet's disease according to the International Criteria for Behçet's Disease and age-matched healthy controls. Serum EBI-3 protein levels will be measured by ELISA.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

You would sign informed consent and be assigned as a Behçet's disease participant or a healthy control. The study will measure serum EBI-3 protein levels (measured by ELISA) from participants. Disease participants will have their disease activity recorded using the Behçet's Disease Current Activity Form (BDCAF); the study will compare EBI-3 levels by activity and by vascular, ocular, or neurological involvement. The registry does not describe any other study procedures or visits.

How the study is structured. Observational, case-control, cross-sectional design. Adult patients with Behçet's disease and age-matched healthy controls give a blood sample at baseline; EBI-3 protein in serum is measured by ELISA. Disease activity and organ involvement are recorded for comparison between groups.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

  • The registry lists this study under Behçet Disease. Does it apply to my diagnosis?
  • This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
  • The registry says recruitment has not started. When is it expected to open, and can I register interest now?
  • No sites are listed on the registry yet. Where will the study take place?
  • Which of the eligibility criteria would need to be checked with tests before I could join?

More on familial Mediterranean fever

This trial is also listed on this site under Behçet's disease.

Clinical trials62 trials listed for familial Mediterranean feverEvery trial the registry lists for familial Mediterranean fever, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in familial Mediterranean fever researchLatest monthly update: September 2026. Includes: Colchicine form change. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start
Sep 26, 2026 (estimated)
Primary completion
Sep 26, 2027 (estimated)
Study completion
Jan 25, 2028 (estimated)
Target enrollment
90 participants (estimated)
Last updated on registry
Sep 28, 2026
Data verified
Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor
Assiut University
Principal investigator
Shrouk Samir Mohamed, Resident Physician, Department of Physical Medicine, Rheumatology and Rehabilitation
Assiut University

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Participating sites

Study locations have not been posted on ClinicalTrials.gov yet. This study is not yet recruiting, so sites may be added when recruitment begins. The central study contact above may be able to tell you about planned sites.

Terms used on this page · explanations by MedicalUpdates.ai

Written informed consent
The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
Inclusion Criteria
The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria
The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials